Deutsches Herzzentrum München, Technische Universität München, Munich, Germany.
EuroIntervention. 2017 Oct 20;13(8):986-993. doi: 10.4244/EIJ-D-16-00871.
The durable polymer platinum-chromium everolimus-eluting stent (PtCr-EES) is a new-generation drug-eluting stent (DES) with a platinum-enriched metallic platform developed to improve the percutaneous treatment of patients with coronary artery disease. We sought to investigate the performance of durable polymer PtCr-EES versus other new-generation DES.
We undertook a meta-analysis of trials in which patients receiving percutaneous coronary intervention (PCI) were randomly assigned to durable polymer PtCr-EES versus other new-generation DES (other DES). Primary efficacy and safety outcomes were target lesion revascularisation (TLR) and definite/probable stent thrombosis (ST), respectively. Secondary outcomes were myocardial infarction (MI), target vessel revascularisation (TVR), death, cardiac death and longitudinal stent deformation (LSD). A total of 11,036 patients in seven trials received a PCI with either durable polymer PtCr-EES (n=6,613) or other DES (n=4,423). This latter group comprised patients treated with biolimus- (n=325), cobalt-chromium everolimus- (n=1,940) or zotarolimus-eluting stents (n=2,158). After a median follow-up of 12 months (interquartile range 12-24), durable polymer PtCr-EES displayed a risk of TLR (odds ratio 0.98, 95% confidence interval [CI]: 0.75-1.29; p=0.90) and definite/probable ST (0.89 [0.55-1.45]; p=0.63) comparable to that of other DES. However, the durable polymer PtCr-EES was associated with a higher risk of LSD (12.05 [1.60-90.71], p=0.02) compared to other DES. There was no significant difference with regard to other secondary outcomes nor was there heterogeneity across trials.
At one-year follow-up, the durable polymer PtCr-EES displays a performance comparable to that of other new-generation DES platforms.
持久聚合物铂铬依维莫司洗脱支架（PtCr-EES）是一种新一代药物洗脱支架（DES），具有富含铂的金属平台，旨在改善经皮冠状动脉介入治疗（PCI）患者的治疗效果。我们旨在研究持久聚合物 PtCr-EES 与其他新一代 DES 的性能。
我们对接受 PCI 的患者随机分配至持久聚合物 PtCr-EES 与其他新一代 DES（其他 DES）的试验进行了荟萃分析。主要疗效和安全性终点分别为靶病变血运重建（TLR）和确定/可能的支架血栓形成（ST）。次要终点包括心肌梗死（MI）、靶血管血运重建（TVR）、死亡、心脏死亡和纵向支架变形（LSD）。共有 7 项试验的 11036 例患者接受了 PCI，其中 6613 例患者接受了持久聚合物 PtCr-EES 治疗，4423 例患者接受了其他 DES 治疗。后者组包括接受生物可吸收（n=325）、钴铬依维莫司（n=1940）或佐他莫司洗脱支架（n=2158）治疗的患者。中位随访 12 个月（四分位间距 12-24）后，持久聚合物 PtCr-EES 的 TLR 风险（优势比 0.98，95%置信区间[CI]：0.75-1.29；p=0.90）和确定/可能的 ST（0.89 [0.55-1.45]；p=0.63）与其他 DES 相当。然而，与其他 DES 相比，持久聚合物 PtCr-EES 与 LSD 的风险增加相关（12.05 [1.60-90.71]，p=0.02）。其他次要终点无显著差异，且各试验之间无异质性。
在一年的随访中，持久聚合物 PtCr-EES 的性能与其他新一代 DES 平台相当。
